TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02336425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 120 mg per 1 mL liquid in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 120 mg per 1 mL liquid in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 120 mg per 1 mL liquid in vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 0 mg per 1 mL liquid in vial
Study: NCT03749135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: anti-IL4-Receptor alpha

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04051086

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Physical examination and Urine and blood samples
Description: Only one visit for each participant : A large majority of visits will be part of patients' usual care~* Medical examination : birth, weight, gender, blood pressure, medical history~* Urine and blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Physical examination and Urine and blood samples
Description: Only one visit for each participant : A large majority of visits will be part of patients' usual care~* Medical examination : birth, weight, gender, blood pressure, medical history~* Urine and blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Urine and blood samples
Description: Only one visit for each participant~* Medical history~* Urine and blood samples
Study: NCT02338063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: 4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
Study: NCT03356613

Intervention type: OTHER
Intervention: test of the Geni tool
Description: The GenI tool built on paramedic's view will be tested.
Study: NCT01608295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone; Viibryd
Description: Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine; Paxil
Description: Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
Study: NCT02331537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavior therapy
Description: Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
Study: NCT02324972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Synthetic SHIP1 activator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03262181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: 5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation
Description: 5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
Study: NCT05762809

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Y-balance test
Description: The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements
Description: Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
Study: NCT00135707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement/Vitamins
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Study: NCT05906654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing History through Active Reminiscence and Photo-imagery (SHARP)
Description: Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
Study: NCT02297425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06459988
Description: The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
Study: NCT02670421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face Heart SMART Program
Description: The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On-line Heart SMART Program
Description: The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mayo Clinic Guide to Stress Free Living
Description: All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mayo Clinic Guide to Stress Free Living
Description: All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
Study: NCT03461783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zorflex Activated Carbon Dressing
Description: Antimicrobial dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: foam, calcium alginate, hydrogel, or compressive dressings
Study: NCT02604823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
Study: NCT00135707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Vitamin C and Vitamin E
Description: Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Study: NCT00922974

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation therapy
Description: Single fraction dose of 8 Gy external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery/SBRT
Description: Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
Study: NCT03260764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short term Multifocal Contact Lenses
Description: wearing Multifocal Contact Lenses for one week

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: short term Multifocal Contact Lenses
Description: wearing Multifocal Contact Lenses for one week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short term Bifocal Spectacles
Description: wearing Bifocal Spectacles for one week

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: short term Bifocal Spectacles
Description: wearing Bifocal Spectacles for one week
Study: NCT01871688

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pelvic floor rehabilitation program with neuromodulation
Description: pelvic floor rehabilitation program with neuromodulation
Study: NCT03924700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biportal endoscopy
Description: Biportal endoscopic spine surgery (BESS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Using microscope for discectomy
Study: NCT01067846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seromycin (D-cycloserine, DCS)
Description: 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
Study: NCT03260764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long term Multifocal Contact Lenses
Description: wearing Multifocal Contact Lenses for one year
Study: NCT01067846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy
Description: All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Cognitive Behavioral Therapy
Description: All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
Study: NCT01396772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE education program
Description: PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care presentation
Description: A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
Study: NCT01791972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Spiromax
Description: Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Spiromax
Description: Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
Study: NCT01422473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnSeal Trio Tissue Sealing Device
Description: For surgery in ligating and dividing vascular tissue during abdominal surgery.
Study: NCT04047173

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Description: RFA with a safe margin, RFA again if residual, no more than 2 times.
Study: NCT03508401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR)
Description: PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echo-Doppler measurements
Description: Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin)).
Study: NCT02193490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNase
Description: DNase 0.1% eye drops four times a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Drug vehicle eye drops four times a day for 8 weeks
Study: NCT04332055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERVIN
Description: ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.
Study: NCT04197375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thermal stress and performance using a pre-cooling protocol
Description: One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Thermal stress and performance without a pre-cooling protocol
Description: During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
Study: NCT02002377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
Study: NCT01250795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAI-05 Influenza Vaccine
Description: injection, vaccine, twice every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAI-05 Influenza Vaccine
Description: injection, vaccine, twice every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAI-05 Influenza Vaccine
Description: injection, vaccine, twice every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAI-05 Influenza Vaccine
Description: injection, vaccine, twice every 3 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT05038605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical metronidazole
Description: Topical application of metronidazole cream on the anal verge every 8 hours after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral metronidazole
Description: Patients received oral metronidazole 500 mg tablets every 8 hours after surgery
Study: NCT03066882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NCD
Description: negative calorie diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCD
Description: low calorie diet
Study: NCT03230604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite
Description: Restorative cavities one, two and five with material Filtek Bulk Fill Composite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite
Description: Restorative cavities one, two and five with material Filtek Bulk Fill Composite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Z 350 Xt Composite
Description: Restorative cavities one, two and five with material Z 350 XT Composite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Z 350 Xt Composite
Description: Restorative cavities one, two and five with material Z 350 XT Composite
Study: NCT02214875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CQI/BTS
Description: Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
Study: NCT00277095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProACT (Adjustable Continence Therapy)
Description: Implantable device to reduce urinary stress incontinence
Study: NCT01930097

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 hours intervention
Description: Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 hours intervention
Description: Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 hours intervention
Description: Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
Study: NCT03568643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.
Study: NCT03541681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid Injections
Description: 1 ml Dexamethasone + 0,5 ml Bupivacain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic Injections
Description: 0,5 ml Bupivacain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic Injections
Description: 0,5 ml Bupivacain